Sample Name
Sample Code
Sample Name
Sample Code
Sample Name
Sample Code
4
Kingchem
301509
5
Hunan Er-kang Pharmaceutical
300267
(FY)Dec 31, 2024 | (Q4)Dec 31, 2024 | (Q3)Sep 30, 2024 | (Q2)Jun 30, 2024 | (Q1)Mar 31, 2024 | (FY)Dec 31, 2023 | (Q4)Dec 31, 2023 | (Q3)Sep 30, 2023 | (Q2)Jun 30, 2023 | (Q1)Mar 31, 2023 | |
---|---|---|---|---|---|---|---|---|---|---|
Total revenue | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
Operating revenue | --0 | --0 | --0 | --0 | --0 | --0 | --0 | --0 | --0 | --0 |
Cost of revenue | ||||||||||
Gross profit | ||||||||||
Operating expense | 10.31%14.7M | 1.09%3.9M | 16.86%3.8M | 148.12%3.7M | -30.14%3.3M | -32.42%13.32M | -30.76%3.86M | -36.18%3.25M | -70.90%1.49M | 20.28%4.72M |
Selling and administrative expenses | 16.33%9.94M | 31.51%3.13M | 19.97%2.4M | 14.50%2.2M | -1.43%2.21M | -16.55%8.54M | -33.70%2.38M | -10.08%2M | -15.95%1.92M | 4.86%2.25M |
-General and administrative expense | 16.33%9.94M | 31.51%3.13M | 19.97%2.4M | 14.50%2.2M | -1.43%2.21M | -16.55%8.54M | -33.70%2.38M | -10.08%2M | -15.95%1.92M | 4.86%2.25M |
Research and development costs | 9.18%10.58M | -21.76%2.19M | 14.64%2.86M | 95.28%2.77M | -7.38%2.76M | -0.08%9.69M | 30.68%2.79M | -15.35%2.49M | -49.84%1.42M | 67.11%2.98M |
Other operating expenses | -18.54%-5.82M | -7.54%-1.41M | -17.42%-1.46M | 31.01%-1.28M | -231.42%-1.68M | -2,093.30%-4.91M | -769.54%-1.31M | -1,598.63%-1.24M | ---1.85M | ---506K |
Operating profit | -10.31%-14.7M | -1.09%-3.9M | -16.86%-3.8M | -148.12%-3.7M | 30.14%-3.3M | 32.42%-13.32M | 30.76%-3.86M | 36.18%-3.25M | 70.90%-1.49M | -20.28%-4.72M |
Net non-operating interest income expense | -69,120.00%-3.45M | -106.25%-3K | -40.63%19K | -43,912.50%-3.51M | 145.78%38K | 100.89%5K | 155.81%48K | 125.60%32K | 104.94%8K | 56.54%-83K |
Non-operating interest income | -31.75%273K | -50.91%54K | -32.77%80K | -44.17%67K | 41.18%72K | 172.11%400K | 50.68%110K | 147.92%119K | 531.58%120K | 628.57%51K |
Non-operating interest expense | 842.78%3.72M | -8.06%57K | -29.89%61K | 3,089.29%3.57M | -74.63%34K | -44.44%395K | -61.01%62K | -49.71%87K | -38.12%112K | -32.32%134K |
Other net income (expense) | 5.17M | 0 | 906K | 4.26M | ||||||
Gain on sale of security | --5.65M | --0 | --960K | --4.69M | ---- | ---- | ---- | ---- | ---- | ---- |
Other non- operating income (expenses) | ---486K | --0 | ---54K | ---432K | ---- | ---- | ---- | ---- | ---- | ---- |
Income before tax | 2.54%-12.98M | -2.44%-3.9M | 10.72%-2.87M | -98.38%-2.94M | 32.13%-3.26M | 34.32%-13.32M | 32.66%-3.81M | 38.32%-3.22M | 71.94%-1.48M | -16.74%-4.81M |
Income tax | ||||||||||
Net income | 2.54%-12.98M | -2.44%-3.9M | 10.72%-2.87M | -98.38%-2.94M | 32.13%-3.26M | 34.32%-13.32M | 32.66%-3.81M | 38.32%-3.22M | 71.94%-1.48M | -16.74%-4.81M |
Net income continuous Operations | 2.54%-12.98M | -2.44%-3.9M | 10.72%-2.87M | -98.38%-2.94M | 32.13%-3.26M | 34.32%-13.32M | 32.66%-3.81M | 38.32%-3.22M | 71.94%-1.48M | -16.74%-4.81M |
Minority interest income | ||||||||||
Net income attributable to the parent company | 2.54%-12.98M | -2.44%-3.9M | 10.72%-2.87M | -98.38%-2.94M | 32.13%-3.26M | 34.32%-13.32M | 32.66%-3.81M | 38.32%-3.22M | 71.94%-1.48M | -16.74%-4.81M |
Preferred stock dividends | ||||||||||
Other preferred stock dividends | ||||||||||
Net income attributable to common stockholders | 2.54%-12.98M | -2.44%-3.9M | 10.72%-2.87M | -98.38%-2.94M | 32.13%-3.26M | 34.32%-13.32M | 32.66%-3.81M | 38.32%-3.22M | 71.94%-1.48M | -16.74%-4.81M |
Basic earnings per share | 54.01%-1.95 | 30.00%-0.49 | 63.00%-0.37 | 23.73%-0.45 | 63.77%-0.75 | 63.39%-4.24 | 70.34%-0.7 | 64.91%-1 | 83.43%-0.59 | 27.37%-2.07 |
Diluted earnings per share | 44.81%-2.34 | 4.29%-0.67 | 63.00%-0.37 | -20.34%-0.71 | 63.77%-0.75 | 63.39%-4.24 | 70.34%-0.7 | 64.91%-1 | 83.43%-0.59 | 27.37%-2.07 |
Dividend per share | ||||||||||
Currency Unit | USD | USD | USD | USD | USD | USD | USD | USD | USD | USD |
Accounting Standards | US-GAAP | US-GAAP | US-GAAP | US-GAAP | US-GAAP | US-GAAP | US-GAAP | US-GAAP | US-GAAP | US-GAAP |
Audit Opinions | Unqualified Opinion with Explanatory Notes | -- | -- | -- | -- | Unqualified Opinion with Explanatory Notes | -- | -- | -- | -- |